Lexeo Therapeutics, Inc. (LXEO) FDA catalysts & readout calendar
Updated ·next FDA decision on the calendar
We do not currently track a confirmed FDA catalyst for Lexeo Therapeutics, Inc.. Any decision listed below was inferred from share-price behaviour and has not been checked against a filing, so there is nothing we have verified to show here yet.
Lexeo Therapeutics, Inc. · no upcoming catalyst on file · 0 past FDA decisions
This page aggregates LXEO's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Common questions
When is the next FDA decision or readout for Lexeo Therapeutics, Inc. (LXEO)?
December 2026. The next catalyst for Lexeo Therapeutics, Inc. is LX1001 (readout). That date is known to the month only. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.
How do stocks like LXEO move into an FDA decision?
We have no measured history for LXEO itself. Across the whole study of 1,855 FDA decisions, the median stock rose 17.9% at its best point in the 120 trading days before the decision, but was only 2.2% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
Where does this LXEO data come from?
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.